Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.72 |
| ▸ | PNP | P00491 | 7/20 | 0.71 |
| ▸ | BLM | P54132 | 2/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | EDNRA | P25101 | 1/20 | 0.71 |
| ▸ | HTR2A | P28223 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | HBB | P68871 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | VCP | P55072 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | HPRT1 | P00492 | 8/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL350397 | 0.88 | TK1 (0.82) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL9960816 | 0.87 | PNP (0.68) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL29286376 | 0.87 | TK1 (0.76) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL18521979 | 0.86 | PNP (0.66) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL3836263 | 0.85 | TK1 (0.92) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL874736 | 0.84 | PNP (0.64) | TK1PNPBLMUSP2TSHR | |
| Tiviciclovir SCHEMBL6944256 | 0.84 | BLM (0.67) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL5181353 | 0.84 | TK1 (0.65) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL571645 | 0.84 | TK1 (1.00) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL455494 | 0.84 | PNP (0.64) | TK1PNPBLMUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105938124-A | Determination method of formaldehyde-DNA adducts in saliva | 国家烟草质量监督检验中心 | 2016-09-14 | — | — | CN | claimed |
| CN-105628848-A | Method for measuring six aldehyde-DNA adducts in saliva | NAT TOBACCO QUALITY SUPERVISION & INSPECTION CT | 2016-06-01 | — | — | CN | claimed |
| US-11185588-B2 | Pharmaceutical dosage forms comprising valganciclovir hydrochloride | HOFFMANN-LA ROCHE INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11000600-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20190117775-A1 | NOVEL PHARMACEUTICAL DOSAGE FORMS COMPRISING VALGANCICLOVIR HYDROCHLORIDE | HOFFMANN-LA ROCHE INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-20180153998-A1 | NOVEL PHARMACEUTICAL DOSAGE FORMS COMPRISING VALGANCICLOVIR HYDROCHLORIDE | HOFFMANN-LA ROCHE INC. (US) | 2018-06-07 | — | — | US | disclosed |
| CN-105938124-A | Determination method of formaldehyde-DNA adducts in saliva | 国家烟草质量监督检验中心 | 2016-09-14 | — | — | CN | disclosed |
| CN-105911164-A | Determination method of formaldehyde-DNA adduct | 国家烟草质量监督检验中心 | 2016-08-31 | — | — | CN | disclosed |
| CN-105628848-A | Method for measuring six aldehyde-DNA adducts in saliva | NAT TOBACCO QUALITY SUPERVISION & INSPECTION CT | 2016-06-01 | — | — | CN | disclosed |
| US-20140179719-A1 | NOVEL AMORPHOUS SOLID DISPERSIONS OF VALGANCICLOVIR HYDROCHLORIDE | CHEEKOORI SREEDHAR (CA) | 2014-06-26 | — | — | US | disclosed |
| CN-101456859-B | Method for preparing antiviral drug valaciclovir | UNIV SOUTH CHINA TECH | 2011-07-20 | — | — | CN | disclosed |
| WO-2010036904-A2 | PREPARATION OF VALGANCICLOVIR AND ITS SALTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-04-01 | — | — | WO | disclosed |
| CN-101456859-A | Method for preparing antiviral drug valaciclovir | UNIV SOUTH CHINA TECH (CN) | 2009-06-17 | — | — | CN | disclosed |
| WO-2008082602-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LIVER DISORDERS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080146591-A1 | Contains non-hygroscopic organic acid as stabilizer; for oral administration, after being constituted in water | BACHYNSKY MARIA OKSANA | 2008-06-19 | — | — | US | disclosed |
| US-7365178-B2 | Acyl-nucleotide probes and methods of their synthesis and use in proteomic analysis | ACTIVX BIOSCIENCES, INC. (US) | 2008-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179719-A1 | NOVEL AMORPHOUS SOLID DISPERSIONS OF VALGANCICLOVIR HYDROCHLORIDE | SEPTIN9, SEPTIN7, TYMP | TK1 47/4885PNP 33/4885BLM 2800/4885 |
| US-11185588-B2 | Pharmaceutical dosage forms comprising valganciclovir hydrochloride | OTC, CYP3A5, RPL35 | TK1 24/4885PNP 1291/4885BLM 2985/4885 |
| US-20180153998-A1 | NOVEL PHARMACEUTICAL DOSAGE FORMS COMPRISING VALGANCICLOVIR HYDROCHLORIDE | OTC, RPL35, SORD | TK1 38/4885PNP 1531/4885BLM 3351/4885 |
| US-20080146591-A1 | Contains non-hygroscopic organic acid as stabilizer; for oral administration, after being constituted in water | OTC, RPL35, RPL26 | TK1 16/4885PNP 1699/4885BLM 4025/4885 |
| US-11000600-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, RBM17 | TK1 1801/4885PNP 3549/4885BLM 1611/4885 |
| US-20190117775-A1 | NOVEL PHARMACEUTICAL DOSAGE FORMS COMPRISING VALGANCICLOVIR HYDROCHLORIDE | OTC, RPL35, SORD | TK1 29/4885PNP 1278/4885BLM 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.